On April 25, 2024, Biodexa Pharmaceuticals Plc entered into a licensing agreement with Emtora Biosciences to develop eRapa™, an oral formulation of rapamycin, for various medical applications. As part of the agreement, Biodexa made an upfront payment of $1.15 million and may incur up to $41.5 million in milestone payments, along with royalties on sales.